Key Pharmacy Recalls Papaverine/Phentolamine Injections Due to Sterility Concerns
Key Pharmacy and Compounding Center is recalling specific lots of Papaverine/Phentolamine injections because the firm cannot assure the sterility of the product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for potential serious, reversible health consequences.
Plain-English summary
Key Pharmacy and Compounding Center is recalling 4 vials of Papaverine/Phentolamine 30/0.5mg/mL Injection. The product is a prescription-only, 5mL glass multiple-dose vial prepared by Key Compounding Pharmacy.
The recall is being conducted due to a lack of assurance of sterility. The firm is recalling sterile compounded drugs within their expiry dates because it cannot guarantee that the product is sterile.
The affected lots are Lot # t11-28-2016@111 (Expiration 5/28/2017) and Lot # 02-10-2017@1 (Expiration 8/9/2017). The product was distributed nationwide in the U.S.A., as well as in Australia and Canada. Consumers and healthcare providers should stop using the product and contact their pharmacist or the recalling firm for instructions on return or disposal.
The recalled product
- Product
- PAPAVERINE/PHENT 5ML MDV 30/0.5MG/ML INJ, Injection, 30/0.5mg/mL, Rx only, 5mL glass/Multiple Dose vial, Prepared by Key Compounding Pharmacy
- Manufacturer
- Key Pharmacy and Compounding Center
- Category
- Drug — Compounded Injectable
- Affected units
- 4
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # t11-28-2016@111
- Exp 5/28/2017
- 02-10-2017@1
- Exp 8/9/2017.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Key Pharmacy and Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Key Pharmacy and Compounding Center
See all →- SevereKey Pharmacy Recalls Pyridoxal-5-Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Sterile Compounded Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- HighKey Pharmacy Recalls Vitamin D3 Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls 5-MTHF Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- Severe
- SevereVital Care Compounder Recalls Papaverine and Phentolamine Vials Due to Sterility Concerns
FDA (Drugs) · 2016-10-05
- HighInjectable Papaverine/Phentolamine Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighFDA Recalls Papaverine/Phentolamine Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2023-02-01
- HighPharmacy Compounded Injection Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- SevereFDA Recalls Papaverine-Phentolamine Injectable Due to Insanitary Compounding Conditions
FDA (Drugs) · 2019-04-17